The Efficacy of Three Months-Prednisolone Therapy for Chronic Eosinophilic Pneumonia
Information source: Hamamatsu University
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Eosinophilic Pneumonia; Chronic Disease
Intervention: prednisolone 0.5mg/kg/day for three months (Drug); prednisolone 0.5mg/kg/day for six months (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Hamamatsu University Official(s) and/or principal investigator(s):
Kingo Chida, MD,PhD, Study Chair, Affiliation: Hamamatsu University
Overall contact:
Naoki Inui, MD,PhD, Phone: 81-53-435-2385, Email: may15@hama-med.ac.jp
Summary
A comparison of 3 months-prednisolone administration with 6 months-prednisolone therapy in
the treatment of chronic eosinophilic pneumonia. Three months-prednisolone administration may
be effective as 6 months-therapy.
Clinical Details
Official title: Phase 4, Randomized Study of Three Months-Prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Efficacy of 3 versus 6 months-prednisolone therapy for chronic eosinophilic pneumonia
Secondary outcome: Safety of 3 versus 6 months-prednisolone therapy for chronic eosinophilic pneumonia
Eligibility
Minimum age: 16 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- biopsy-proven chronic eosinophilic pneumonia
Exclusion Criteria:
- patients who received oral glucocorticosteroid (more than 10mg)
- immunosuppressive drug
Locations and Contacts
Naoki Inui, MD,PhD, Phone: 81-53-435-2385, Email: may15@hama-med.ac.jp
Hamamatsu University School of Medicine, Hamamatsu, Japan; Recruiting
Naoki Inui, MD,PhD, Phone: 81-53-435-2385, Email: may15@hama-med.ac.jp
Additional Information
Starting date: June 2007
Ending date: March 2010
Last updated: March 10, 2008
|
